Results 171 to 180 of about 209,210 (339)

Tandem High‐Dose Chemotherapy and Autologous Stem Cell Transplantation for Osteosarcoma with Initial Pulmonary Metastases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Although the survival rates of patients with localized osteosarcoma have significantly improved, metastatic osteosarcoma still has a poor prognosis. The role of high‐dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in high‐risk osteosarcoma remains unclear compared to that of conventional chemotherapy, and an ...
Hyun Jin Park, Kyung Taek Hong, Jung Yoon Choi, Bo Kyung Kim, Han‐Soo Kim, Samina Park, Sung‐Hye Park, Jung‐Eun Cheon, Hyoung Jin Kang   +8 more
wiley   +1 more source

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment [PDF]

, 2017
A Rai, AG Tolcher, AX Zhu, Caio Max S Rocha-Lima, David Portnoy, DP Brooks, E Gabriela Chiorean, E Suzuki, J Albores-Saavedra, J Nelson, J Valle, JE Rogers, JF Guion-Dussere, Jitendra Gandhi, L Goyal, M Yanagisawa, Manik Amin, NV Rajeshkumar, NV Rajeshkumar, P Papakostas, R Pazdur, Richard Kim, RK Jain, RL Siegel, S He, SC Lee, SY Oh, T Sasaki, T Walter, Tao Song, William P Harris   +30 more
core   +3 more sources

Adult‐Onset Dystonia‐Parkinsonism: Do Not Forget SERAC1

Movement Disorders Clinical Practice, EarlyView.
Giulia Scacciatella, Costanza Masetti, Vidal Yahya, Mauro Treddenti, Gaia Oggioni, Tommaso Bocci, Laura Campiglio, Manuela Zardoni, Chiara Rosci, Marta Pengo, Chiara Manfredi, Roberto Del Bo, Edoardo Monfrini, Alessio Di Fonzo, Maurizio Inghilleri, Alberto Priori   +15 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders

Movement Disorders Clinical Practice, EarlyView.
Charles Palmer, Alexander McClanahan, Federico Rodriguez‐Porcel   +2 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Maribavir's anti‐cytomegalovirus (CMV) activity and favorable safety/tolerability profile is a welcomed addition to the CMV treatment armamentarium. To further characterize pharmacokinetic (PK) and exposure–response relationships of maribavir in transplant recipients with CMV, a population PK model was updated with data from the AURORA study ...
Kefeng Sun, Claudia Jomphe, Nathalie H. Gosselin, Leon Pheng, Chandrasekar Durairaj, Yaming Hang, Indranil Bhattacharya   +6 more
wiley   +1 more source

Infecciones intrahospitalarias en pacientes pediátricos con enfermedades hematológicas, 2006-2009 Nosocomial infections in pediatric patients with hematological diseases, 2006-2009

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2012
Se realizó un estudio descriptivo transversal en el Servicio de Pediatría del Instituto de Hematología e Inmunología, en el período comprendido entre diciembre de 2006 y marzo de 2009.
Librada Martell-Martorell, Alberto Arencibia-Núñez   +1 more
doaj  

TRANSIENT NEUTROPENIA OF CHILDHOOD [PDF]

, 1984
Rose Valiaveedan, Suresh Gururaja Rao, S. Miller, Audrey Brown   +3 more
openalex   +1 more source

The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?

Movement Disorders, EarlyView.
Daniel Weintraub, Izabelle Schoen
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure‐response (E‐R) relationships of selected efficacy and ...
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
wiley   +1 more source